Pfizer, Inc.

PFE

US7170811035

Pharmaceuticals

Market Closed - Nyse Other stock markets 04:00:39 2024-04-23 pm EDT			5-day change	1st Jan Change
26.32 ^USD	+0.23%		+2.45%	-8.58%

Apr. 23	Edwards Lifesciences Corporation: The story continues
Apr. 23	Pfizer vs Moderna battle over COVID vaccine patents begins in UK	RE

PFIZER INC : Goldman Sachs reiterates its Neutral rating

May 25, 2022 at 08:36 am EDT

Initially Neutral on the company, Goldman Sachs's analyst Chris Shibutani maintained his recommendation. The target price remains unchanged at USD 51.

Latest news about Pfizer, Inc.

Edwards Lifesciences Corporation: The story continues	Apr. 23
Pfizer vs Moderna battle over COVID vaccine patents begins in UK	Apr. 23	RE
Pfizer: new Emblaveo antibiotic approved in the EU	Apr. 22	CF
Pfizer's Emblaveo Receives European Commission Marketing Approval	Apr. 22	MT
European Commission Approves Pfizer?s Emblaveo® for Patients with Multidrug-Resistant Infections and Limited Treatment Options	Apr. 22	CI
Sector Update: Health Care Stocks Retreating Late Afternoon	Apr. 17	MT
Sector Update: Health Care	Apr. 17	MT
Connect Biopharma Terminates Agreement on Antiallergic Candidate With Pfizer	Apr. 17	MT
Tara Health Foundation Files an Exempt Solicitation Statement with Securities and Exchange Commission	Apr. 16	CI
News Highlights : Top Financial Services News of the Day - Monday at 11 AM ET	Apr. 15	DJ
Global markets live: Goldman Sachs, Apple, Salesforce, Boeing Tesla...	Apr. 15
Novavax Shareholder Shah Capital Pushes to Add 2 Nominees to Company's Board	Apr. 15	MT
Market outlook is uncertain, but optimism prevails	Apr. 15
News Highlights : Top Financial Services News of the Day - Monday at 7 AM ET	Apr. 15	DJ
News Highlights : Top Financial Services News of the Day - Monday at 12 AM ET	Apr. 15	DJ
PFIZER INC : JP Morgan remains Neutral	Apr. 12	ZD
Skanska Trims Scope of Work for Biomanufacturing Facility Project in US	Apr. 12	MT
PFIZER INC : Berenberg remains Neutral	Apr. 10	ZD
Health Care Stocks Steady, Moderna Climbs -- Health Care Roundup	Apr. 09	DJ
Sector Update: Health Care Stocks Mixed in Late Afternoon Trading	Apr. 09	MT
Sector Update: Health Care	Apr. 09	MT
Pfizer Says Phase 3 Trial of Abrysvo for Respiratory Syncytial Virus Disease Meets Primary Endpoints	Apr. 09	MT
Pfizer's RSV Vaccine Meets Primary Endpoints in Study of Participants Under 60 Years; Seeks Expanded Access	Apr. 09	MT
Pfizer: positive results for RSV in adults	Apr. 09	CF
Pfizer's Abrysvo Hits Key Goals in Adults at Increased RSV Risk	Apr. 09	DJ

Pfizer, Inc. is the world's leading pharmaceutical group. Net sales break down by family of products as follows: - primary care products (72.8%): medicines used in internal medicine, vaccines, medicines for the prevention and treatment of Covid-19, antivirals, mRNA-based products, etc.; - specialty care products (13.8%): medicines used in immunology, in hospitals and for the treatment of rare diseases, anti-inflammatory medicines, etc.; - oncology products (12.1%); - other (1.3%). At the end of 2022, the group had more than 35 manufacturing sites worldwide. Net sales are distributed geographically as follows: the United States (42.3%), Europe (21.9%) and other (35.8%).

Sector

Pharmaceuticals

Calendar

2024-04-25 - Annual General Meeting

Related indices

S&P 500

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

Pfizer, Inc: A cycle for nothing?

December 14, 2023 at 10:58 am EST

Albert Bourla, Pfizer CEO (full interview): mRNA, acquisitions, weight-loss drugs

October 31, 2023 at 04:50 pm EDT

More Strategies

Ratings for Pfizer, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

26.26 USD

Average target price

31.62 USD

Spread / Average Target

+20.41%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
PFIZER, INC.	-8.58%	149B
ELI LILLY AND COMPANY	+27.92%	659B
NOVO NORDISK A/S	+27.68%	557B
JOHNSON & JOHNSON	-4.59%	359B
MERCK & CO., INC.	+16.38%	322B
ABBVIE INC.	+9.39%	297B
ASTRAZENECA PLC	+6.30%	215B
NOVARTIS AG	+4.80%	210B
ROCHE HOLDING AG	-6.05%	200B
AMGEN INC.	-4.99%	146B

Other Pharmaceuticals

Pfizer, Inc.

Equities

PFE

US7170811035

Pharmaceuticals

PFIZER INC : Goldman Sachs reiterates its Neutral rating

Latest news about Pfizer, Inc.

Chart Pfizer, Inc.

Company Profile

Income Statement Evolution

Analysis / Opinion

Ratings for Pfizer, Inc.

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Pharmaceuticals